Aminoglycoside Antibacterials

A category of amino glycoside antibacterials. Must have an amino group attached to a glycoside and have antibacterial effects. Relation to Streptomyces spp. is considered important, but is not enough alone to allow for categorization here. Structurally, it must be an aminoglycoside. It must have antibacterial properties. It potentially came from a Streptomycin spp.
DrugDrug NameDrug Indication
DB00479AmikacinThe amikacin sulfate injection is indicated in the short-term treatment of serious bacterial infections due to susceptible strains of gram-negative bacteria, including Pseudomonas species, Escherichia coli, species of indole-positive and indole-negative Proteus, Providencia species, Klebsiella-Enterobacter-Serratia species, as well as Acinetobacter (Mima-Herellea) species [F1954]. Clinical studies have shown amikacin sulfate injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery) [F1954]. Clinical studies have shown amikacin also to be effective in serious, complicated, and recurrent urinary tract infections due to the above organisms. Aminoglycosides, including amikacin, are not indicated in uncomplicated first-time episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics which are less toxic [F1954]. In September 2018, a new indication with a new dosage route was approved for this drug. Amikacin liposome inhalation suspension was approved for the treatment of lung disease caused by a group of bacteria, Mycobacterium avium complex (MAC) in a limited population of patients with the disease who do not respond to conventional treatment (refractory disease) [L4673]. This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6 of treatment. Clinical benefit has not yet been established [FDA label]. **Important notes regarding Staphylococcus and Sensitivity testing:** Staphylococcus aureus, including methicillin-resistant strains, is the principal Gram-positive organism sensitive to amikacin. The use of amikacin in the treatment of staphylococcal infections should be restricted only to second-line therapy, and should be limited to only those patients suffering from severe infections caused by susceptible strains of staphylococcus species who have failed to show sensitivity to other available antibiotics [F1949]. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be used as initial therapy in suspected gram-negative infections and therapy may be initiated before obtaining the results of susceptibility testing [FDA label], [F1949], [F1954].
DB00684TobramycinFor the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.
DB00798GentamicinFor treatment of serious infections caused by susceptible strains of the following microorganisms: P. aeruginosa, Proteus species (indole-positive and indole-negative), E. coli, Klebsiella-Enterobactor-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative).
DB00994NeomycinTopical uses include treatment for superficial eye infections caused by susceptible bacteria (used in combination with other antiinfectives), treatment of otitis externa caused by susceptible bacteria, treatment or prevention of bacterial infections in skin lesions, and use as a continuous short-term irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters. May be used orally to treat hepatic encephalopathy, as a perioperative prophylactic agent, and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic E. coli (EPEC).
DB01082StreptomycinFor the treatment of tuberculosis. May also be used in combination with other drugs to treat tularemia (Francisella tularensis), plague (Yersia pestis), severe M. avium complex, brucellosis, and enterococcal endocarditis (e.g. E. faecalis, E. faecium).
DB00452FramycetinFor the treatment of bacterial blepharitis, bacterial bonjunctivitis, corneal injuries, corneal ulcers and meibomianitis. For the prophylaxis of ocular infections following foreign body removal
DB00955NetilmicinFor the treatment of bacteremia, septicaemia, respiratory tract infections, skin and soft-tissue infection, burns, wounds, and peri-operative infections caused by susceptible strains.
DB01172KanamycinFor treatment of infections where one or more of the following are the known or suspected pathogens: E. coli, Proteus species (both indole-positive and indole-negative), E. aerogenes, K. pneumoniae, S. marcescens, and Acinetobacter species.
DB01421ParomomycinFor the treatment of acute and chronic intestinal amebiasis (it is not effective in extraintestinal amebiasis). Also for the management of hepatic coma as adjunctive therapy.
DB03615RibostamycinNot Available
DB04263GeneticinNot Available
DB04626ApramycinFor the treatment of bacterial infections in animals.
DB04729Gentamicin C1aNot Available
DB04808NeamineNot Available
DB06696ArbekacinArbekacin is used for the short term treatment of multi-resistant bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA).
DB08437PuromycinNot Available
DB11512DihydrostreptomycinNot Available
DB12604SisomicinNot Available
DB12615PlazomicinPlazomicin is indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis, who have limited or no alternative treatment options. It should only be used to treat infections that are proven or strongly suspected to be caused by susceptible microorganisms [FDA Label].
DB00314CapreomycinUsed in the treatment of tuberculosis in combination with other drugs.
DB00803ColistinFor the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.
DrugDrug NameTargetType
DB00479Amikacin30S ribosomal protein S12target
DB00684Tobramycin30S ribosomal protein S12target
DB00684Tobramycin16S rRNAtarget
DB00684TobramycinAminoglycoside 2'-N-acetyltransferaseenzyme
DB00798Gentamicin30S ribosomal protein S12target
DB00798Gentamicin16S rRNAtarget
DB00798GentamicinLow-density lipoprotein receptor-related protein 2target
DB00798GentamicinSolute carrier family 22 member 6transporter
DB00798GentamicinNH(3)-dependent NAD(+) synthetasetarget
DB00798GentamicinDihydrofolate reductasetarget
DB00994Neomycin30S ribosomal protein S12target
DB00994Neomycin16S rRNAtarget
DB00994NeomycinExtracellular calcium-sensing receptortarget
DB01082Streptomycin30S ribosomal protein S12target
DB01082Streptomycin16S rRNAtarget
DB01082StreptomycinSolute carrier family 22 member 6transporter
DB01082StreptomycinProtein-arginine deiminase type-4target
DB00452Framycetin30S ribosomal protein S12target
DB00452Framycetin16S rRNAtarget
DB00452FramycetinC-X-C chemokine receptor type 4target
DB00955Netilmicin30S ribosomal protein S12target
DB00955Netilmicin16S rRNAtarget
DB01172Kanamycin30S ribosomal protein S12target
DB01172Kanamycin16S rRNAtarget
DB01172KanamycinAminoglycoside 2'-N-acetyltransferaseenzyme
DB01172KanamycinKanamycin nucleotidyltransferaseenzyme
DB01172KanamycinAminoglycoside 3'-phosphotransferaseenzyme
DB01421Paromomycin16S rRNAtarget
DB01421Paromomycin30S ribosomal protein S10target
DB03615RibostamycinProtein disulfide-isomerasetarget
DB03615Ribostamycin30S ribosomal protein S12target
DB03615RibostamycinAminoglycoside N(6')-acetyltransferase type 1target
DB03615RibostamycinAminoglycoside 2'-N-acetyltransferasetarget
DB03615RibostamycinAminoglycoside 2'-N-acetyltransferaseenzyme
DB04263GeneticinOrnithine decarboxylasetarget
DB04626Apramycin16S rRNAtarget
DB04729Gentamicin C1a30S ribosomal protein S12target
DB04729Gentamicin C1a16S rRNAtarget
DB06696Arbekacin30S ribosomal protein S12target
DB08437Puromycin60S ribosomal protein L10-liketarget
DB08437Puromycin60S ribosomal protein L13atarget
DB08437Puromycin60S ribosomal protein L23target
DB08437Puromycin60S ribosomal protein L15target
DB08437Puromycin60S ribosomal protein L19target
DB08437Puromycin60S ribosomal protein L23atarget
DB08437PuromycinProbable ribosome biogenesis protein RLP24target
DB08437Puromycin60S ribosomal protein L26-like 1target
DB08437Puromycin60S ribosomal protein L8target
DB08437Puromycin60S ribosomal protein L37target
DB08437Puromycin60S ribosomal protein L3target
DB08437Puromycin60S ribosomal protein L11target
DB08437PuromycinLeucyl/phenylalanyl-tRNA--protein transferasetarget
DB12615PlazomicinMultidrug and toxin extrusion protein 1transporter
DB12615PlazomicinMultidrug and toxin extrusion protein 2transporter
DB12615Plazomicin30S ribosomal protein S14target
DB12615Plazomicin30S ribosomal protein S11target
DB00314Capreomycin70S ribosometarget
DB00803ColistinBacterial outer membranetarget